How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/autologous-transplantation-using-bexxar-beam.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Autologous transplantation using Bexxar/BEAM — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Autologous transplantation using Bexxar/BEAM (Autologous transplantation using Bexxar/BEAM) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Chemotherapy regimen with autologous stem cell transplantation. Area: Oncology.

phase 3 Chemotherapy regimen with autologous stem cell transplantation CD20 (if Bexxar component); non-specific cytotoxic chemotherapy (BEAM) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Autologous transplantation using Bexxar/BEAM (Autologous transplantation using Bexxar/BEAM) — National Heart, Lung, and Blood Institute (NHLBI). Bexxar/BEAM is a high-dose chemotherapy regimen (BEAM: carmustine, etoposide, cytarabine, melphalan) followed by autologous stem cell transplantation to treat lymphomas by delivering intensive chemotherapy and restoring bone marrow function.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Autologous transplantation using Bexxar/BEAM TARGET	Autologous transplantation using Bexxar/BEAM	National Heart, Lung, and Blood Institute (NHLBI)	phase 3	Chemotherapy regimen with autologous stem cell transplantation	CD20 (if Bexxar component); non-specific cytotoxic chemotherapy (BEAM)
R-mNHL-BFM-90 + auto-SCT	R-mNHL-BFM-90 + auto-SCT	National Research Center for Hematology, Russia	phase 3	Rituximab-based chemotherapy regimen with autologous stem cell transplantation	CD20

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Chemotherapy regimen with autologous stem cell transplantation class)

National Heart, Lung, and Blood Institute (NHLBI) · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Autologous transplantation using Bexxar/BEAM — Competitive Intelligence Brief. https://druglandscape.com/ci/autologous-transplantation-using-bexxar-beam. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab